Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Blood (2024) 143 (7): 592–596.

https://doi.org/10.1182/blood.2023022080

Published: 2024

Includes: Supplemental data

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

Blood (2023) 142 (Supplement 1): 205.

https://doi.org/10.1182/blood-2023-177673

Published: 2023

Journal Articles

Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non-Lenalidomide-Based Treatments in the Real-World MM-034 Study

Michele Cavo, Sujith Dhanasiri, Valerio De Stefano, Angel Ramírez Payer, Martin Wiesholzer, Yvonne Tromp, Meegahage Ratnakanthi Perera, Valentine Richez-Olivier, Maciej Gil, David Bernasconi, Barbara Gamberi

Blood (2022) 140 (Supplement 1): 7195–7196.

https://doi.org/10.1182/blood-2022-162493

Published: 2022

Journal Articles

Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure

Karthik Ramasamy, Niels Abildgaard, Marie-Christiane Vekemans, Barbara Gamberi, Angel Ramírez Payer, Gillian Millar, Annalisa Ansaloni, Margaret Atiba-Davies, David Bernasconi, Torben Plesner, Sujith Dhanasiri

Blood (2022) 140 (Supplement 1): 10000–10001.

https://doi.org/10.1182/blood-2022-162529

Published: 2022

Journal Articles

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137743

Published: 2020

Journal Articles

The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Norbert Grząśko, MD PhD, Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Jan Dürig, Sara Bringhen, Mattia D'Agostino, MD, Barbara Gamberi, Elena Rivolti, MD, Angelo Vacca, MD PhD, Roberto Ria, MD, Artur Jurczyszyn, MD, Jorge Castellano Acosta, MD, Doris Lang, Guy Lemaillet, PhD, Bansod Sudhir, MD, Monika Szarejko, MD

Blood (2019) 134 (Supplement_1): 1899.

https://doi.org/10.1182/blood-2019-129827

Published: 2019

Journal Articles

MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial

Blood (2019) 134 (Supplement_1): 4321.

https://doi.org/10.1182/blood-2019-125134

Published: 2019

Journal Articles

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

Xavier Leleu, MD PhD, Jo Caers, MD PhD, Barbara Gamberi, MD, Maaike Söhne, MD, Sonja Heibl, MD, Florence Suzan, MD, Abeera Mohammad, Sally Wetten, Evangelos Terpos, MD

Blood (2019) 134 (Supplement_1): 5578.

https://doi.org/10.1182/blood-2019-122938

Published: 2019

Journal Articles

Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

Michele Cavo, Valerio De Stefano, MD, Angel Ramirez Payer, Martin Wiesholzer, Yvonne Tromp, Gaëtan Vanstraelen, Baerbel Schaedlich, Richez Valentine, Sujith Dhanasiri, Elisabeth Kueenburg, Barbara Rosettani, Claire Martin, Stefano Pozzi, Pamela Bacon, Barbara Gamberi

Blood (2019) 134 (Supplement_1): 5580.

https://doi.org/10.1182/blood-2019-124555

Published: 2019

Journal Articles

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Eftathios Kastritis, Evangelos Terpos, MD PhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, MD, Eirini Katodritou, MD, Barbara Gamberi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Gavriatopoulou, MD, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1881.

https://doi.org/10.1182/blood-2019-124630

Published: 2019

Journal Articles

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

Blood (2019) 134 (Supplement_1): 3119.

https://doi.org/10.1182/blood-2019-124298

Published: 2019

Journal Articles

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

Blood (2018) 132 (Supplement 1): 257.

https://doi.org/10.1182/blood-2018-99-111321

Published: 2018

Journal Articles

MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Monika Szarejko, Artur Jurczyszyn, MD, Jan Dürig, Sara Bringhen, Barbara Gamberi, MD, Angelo Vacca, Jorge Castellano Acosta, MD, Guy Lemaillet, PhD, Cedric Cortijo, PhD, Bansod Sudhir, Norbert Grząśko, MDPhD

Blood (2018) 132 (Supplement 1): 1980.

https://doi.org/10.1182/blood-2018-99-112859

Published: 2018

Journal Articles

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Blood (2018) 132 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2018-99-115340

Published: 2018

Journal Articles

Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study

Niels Abildgaard, MD PhD, Marie-Christiane Vekemans, Barbara Gamberi, MD, Francesco Di Raimondo, MD, Angel Ramirez Payer, Charalampia Kyriakou, Alain Kentos, Elisabeth Kueenburg, Antonia Di Micco, Barbara Rosettani, Pamela Bacon, Margaret Atiba-Davies, Torben Plesner, MD DSc

Blood (2018) 132 (Supplement 1): 3286.

https://doi.org/10.1182/blood-2018-99-111906

Published: 2018

Journal Articles

Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study

Blood (2017) 130 (Supplement 1): 397.

https://doi.org/10.1182/blood.V130.Suppl_1.397.397

Published: 2017

Journal Articles

High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation

Blood (2017) 130 (Supplement 1): 394.

https://doi.org/10.1182/blood.V130.Suppl_1.394.394

Published: 2017

Journal Articles

Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy

Stefania Oliva, MD, Manuela Gambella, Alessandra Larocca, Stefano Spada, Eleonora Marzanati, Barbara Mantoan, Sara Grammatico, Concetta Conticello, MD, Barbara Gamberi, Massimo Offidani, Anna Marina Liberati, Chiara Pautasso, Paola Omedé, Antonio Palumbo, MD, Mario Boccadoro

Blood (2016) 128 (22): 4409.

https://doi.org/10.1182/blood.V128.22.4409.4409

Published: 2016

Journal Articles

Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)

Blood (2016) 128 (22): 991.

https://doi.org/10.1182/blood.V128.22.991.991

Published: 2016

Journal Articles

Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial

Blood (2016) 128 (22): 992.

https://doi.org/10.1182/blood.V128.22.992.992

Published: 2016

NARROW

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non-Lenalidomide-Based Treatments in the Real-World MM-034 Study

Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study

Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study

High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation

Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy

Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)

Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only